Neurogenic and Neurotrophic Effects of BDNF Peptides in Mouse Hippocampal Primary Neuronal Cell Cultures
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
The level of brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family, is down regulated in Alzheimer's disease (AD), Parkinson's disease (PD), depression, stress, and anxiety; conversely the level of this neurotrophin is increased in autism spectrum disorders. Thus, modulating the level of BDNF can be a potential therapeutic approach for nervous system pathologies. In the present study, we designed five different tetra peptides (peptides B-1 to B-5) corresponding to different active regions of BDNF. These tetra peptides were found to be non-toxic, and they induced the expression of neuronal markers in mouse embryonic day 18 (E18) primary hippocampal neuronal cultures. Additionally, peptide B-5 induced the expression of BDNF and its receptor, TrkB, suggesting a positive feedback mechanism. The BDNF peptides induced only a moderate activation (phosphorylation at Tyr 706) of the TrkB receptor, which could be blocked by the Trk's inhibitor, K252a. Peptide B-3, when combined with BDNF, potentiated the survival effect of this neurotrophin on H(2)O(2)-treated E18 hippocampal cells. Peptides B-3 and B-5 were found to work as partial agonists and as partial antagonists competing with BDNF to activate the TrkB receptor in a dose-dependent manner. Taken together, these results suggest that the described BDNF tetra peptides are neurotrophic, can modulate BDNF signaling in a partial agonist/antagonist way, and offer a novel therapeutic approach to neural pathologies where BDNF levels are dysregulated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It is often observed that in the presence of the endogenous ligand, a synthetic molecule presents antagonistic properties.”
From Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression (2018) · cites this paper as Cardenas-Aguayo Mdel et al. 2013
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Exercise: a behavioral intervention to enhance brain health and plasticity
Cotman, C. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(02)02143-4 · Cited by 2,739 · cited 1×
“Physical exercise increases BDNF level in the hippocampus and the cortex, and may enhance learning and memory, synaptic plasticity, and neurogenesis [34].”
BackgroundNeurotrophins and their receptors: A convergence point for many signalling pathways
Chao, M. V. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1078 · Cited by 2,298 · cited 2×
“In contrast to the nonpeptide origin of the small molecules previously used [2] for activating TrkB pathway, these compounds (B-1 to B-5) which also modulate this pathway, are tetrapeptides (derived from the active site of BDNF).”
BackgroundNeurotrophin signal transduction in the nervous system
Kaplan, D. R., & Miller, F. D. (2000) · Current Opinion in Neurobiology · doi:10.1016/s0959-4388(00)00092-1 · Cited by 1,944 · cited 2×
“necrosis factor (TNF) receptor super family [1,15], and minimally”
BackgroundSustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780 · cited 1×
“Drugs that are able to increase BDNF level in the brain include antidepressants [38] e.”
BackgroundBinder (2004) · doi:10.1080/08977190410001723308 · Cited by 1,481 · cited 4×
“furin generating the mature neurotrophin (molecular weight,14–26 KDa) [13,14].”
BackgroundInfluentialNew insights into BDNF function in depression and anxiety
Martinowich, K., Manji, H., & Lu, B. (2007) · Nature Neuroscience · doi:10.1038/nn1971 · Cited by 1,221 · cited 1×
“Additionally, the expression level of BDNF is also reported to be reduced in Parkinson’s disease (PD), depression, and stress [8,9].”
BackgroundNeuronal Activity–Induced Gadd45b Promotes Epigenetic DNA Demethylation and Adult Neurogenesis
Ma, D. K., Jang, M.-H., Guo, J. U., Kitabatake, Y., Chang, M.-L., Pow-anpongkul, N., Flavell, R. A., Lu, B., Ming, G.-L., & Song, H. (2009) · Science · doi:10.1126/science.1166859 · Cited by 924
BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease
Phillips, H. S., Hains, J. M., Armanini, M., Laramee, G. R., Johnson, S. A., & Winslow, J. W. (1991) · Neuron · doi:10.1016/0896-6273(91)90273-3 · Cited by 921 · cited 1×
“late stages of the disease has been reported [3–7].”
BackgroundPotential therapeutic uses of BDNF in neurological and psychiatric disorders
Nagahara, A. H., & Tuszynski, M. H. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3366 · Cited by 867 · cited 2×
“Alternatively, direct administration of BDNF into the CNS to achieve beneficial neurotrophic effects is a promising approach [27–29], however, there are also some considerations with this strategy that need to be taken into account.”
BackgroundFunctional Interactions of Neurotrophins and Neurotrophin Receptors
Bothwell, M. (1995) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.18.030195.001255 · Cited by 833 · cited 1×
“necrosis factor (TNF) receptor super family [1,15], and minimally”
BackgroundEpigenetic Regulation of bdnf Gene Transcription in the Consolidation of Fear Memory
Lubin, F. D., Roth, T. L., & Sweatt, J. D. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.1786-08.2008 · Cited by 793 · cited 1×
“Fear conditioning has been shown to differentially regulate the expression of BDNF mRNAs, following BDNF DNA methylation [36,37].”
BackgroundConverting a Peptide into a Drug: Strategies to Improve Stability and Bioavailability
Adessi, C., & Soto, C. (2002) · Current Medicinal Chemistry · doi:10.2174/0929867024606731 · Cited by 614
New insights into brain BDNF function in normal aging and Alzheimer disease
Tapia-Arancibia, L., Aliaga, E., Silhol, M., & Arancibia, S. (2008) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.07.007 · Cited by 571 · cited 1×
“BDNF-induced TrkB phosphorylation and dendritic spine formation by modulating the signaling and trafficking of TrkB [5,12].”
BackgroundTrk receptor tyrosine kinases: A bridge between cancer and neural development
Nakagawara, A. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00530-4 · Cited by 495 · cited 1×
“In the case of cancer, it can be useful to find a molecule that works as an antagonist of Trk receptors, since these receptors by virtue of their roles in the regulation of growth, differentiation and programmed cell death are reported to be involved in oncogenesis [61].”
BackgroundA controlled trial of recombinant methionyl human BDNF in ALS
The BDNF Study Group (Phase III) (1999) · Neurology · doi:10.1212/wnl.52.7.1427 · Cited by 451
Yang, J., Siao, C.-J., Nagappan, G., Marinic, T., Jing, D., McGrath, K., Chen, Z.-Y., Mark, W., Tessarollo, L., Lee, F. S., et al. (2009) · Nature Neuroscience · doi:10.1038/nn.2244 · Cited by 449 · cited 3×
“neurons make and secrete significant amounts of endogenous BNDF [18].”
BackgroundInfluentialLee, J., Duan, W., Long, J. M., Ingram, D. K., & Mattson, M. P. (2000) · Journal of Molecular Neuroscience · doi:10.1385/jmn:15:2:99 · Cited by 408 · cited 1×
“Caloric restriction also affects the level of BDNF [35].”
BackgroundSmall molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents
Massa, S. M., Yang, T., Xie, Y., Shi, J., Bilgen, M., Joyce, J. N., Nehama, D., Rajadas, J., & Longo, F. M. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41356 · Cited by 406 · cited 1×
“Small molecules that mimic a particular ligand, like in the case of the peptides used in the present study, can bind to their receptors and disrupt protein-protein interactions inhibiting the functions they mediate, or they could act as activating ligands, though there may be differences from the natural ligand with r…”
BackgroundBiosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF
Matsumoto, T., Rauskolb, S., Polack, M., Klose, J., Kolbeck, R., Korte, M., & Barde, Y.-A. (2008) · Nature Neuroscience · doi:10.1038/nn2038 · Cited by 360 · cited 1×
“[17].”
Dopamine Partial Agonists: A New Class of Antipsychotic
Lieberman, J. A. (2004) · CNS Drugs · doi:10.2165/00023210-200418040-00005 · Cited by 340
Ji, Y., Pang, P. T., Feng, L., & Lu, B. (2005) · Nature Neuroscience · doi:10.1038/nn1381 · Cited by 325 · cited 1×
“BDNF-induced TrkB phosphorylation and dendritic spine formation by modulating the signaling and trafficking of TrkB [5,12].”
BackgroundBehl, C., & Moosmann, B. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00883-3 · Cited by 302 · cited 1×
“The prevention of oxidative stress and the reduction in reactive oxygen species (ROS) are considered to be promising approaches for neuroprotection in neurodegenerative diseases [51].”
BackgroundReview of Lithium Effects on Brain and Blood
Young, W. (2009) · Cell Transplantation · doi:10.3727/096368909x471251 · Cited by 287 · cited 1×
“lithium increases BDNF concentrations in serum by 30% [39], and ampakines increase BDNF and improve stabilization of LTP and long-term memory in a mouse model of Huntington’s disease [40].”
BackgroundChao, M. V., & Bothwell, M. (2002) · Neuron · doi:10.1016/s0896-6273(01)00573-6 · Cited by 278 · cited 2×
“furin generating the mature neurotrophin (molecular weight,14–26 KDa) [13,14].”
BackgroundSimmons, D. A., Rex, C. S., Palmer, L., Pandyarajan, V., Fedulov, V., Gall, C. M., & Lynch, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811228106 · Cited by 261
Partial agonists, full agonists, antagonists: dilemmas of definition
Hoyer, D., & Boddeke, H. W. G. M. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90129-8 · Cited by 237 · cited 1×
“While in the absence of a full agonist, partial agonists show functional agonist activity and bind to the receptor to produce a response [46–48].”
BackgroundThe p75 neurotrophin receptor and neuronal apoptosis
Barrett, G. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00056-8 · Cited by 226 · cited 1×
“[16]; instead, the activation of the TrkB receptor alone, as”
BackgroundCounts, S. E., & Mufson, E. J. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.4.263 · Cited by 222 · cited 1×
“late stages of the disease has been reported [3–7].”
BackgroundThe expanding role of BDNF: a therapeutic target for Alzheimer's disease?
Fumagalli, F., Racagni, G., & Riva, M. A. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500337 · Cited by 173 · cited 1×
“late stages of the disease has been reported [3–7].”
BackgroundShedding light into the role of BDNF in the pharmacotherapy of Parkinson's disease
Fumagalli, F., Racagni, G., & Riva, M. A. (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500360 · Cited by 150 · cited 1×
“Additionally, the expression level of BDNF is also reported to be reduced in Parkinson’s disease (PD), depression, and stress [8,9].”
BackgroundAdvances in small molecules promoting neurotrophic function
PRICE, R., MILNE, S., SHARKEY, J., & MATSUOKA, N. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.03.005 · Cited by 148 · cited 2×
“Given that these compounds are short peptide mimetic molecules of the neurotrophic factor, in most of the cases they should be able to cross the BBB when administered peripherally [19,20,41,42].”
BackgroundBrain-Derived Neurotrophic Factor
Binder, D. K. (2003) · Elsevier eBooks · doi:10.1016/b0-12-341103-3/00037-1 · Cited by 147
Correia, C. T., Coutinho, A. M., Sequeira, A. F., Sousa, I. G., Lourenço Venda, L., Almeida, J. P., Abreu, R. L., Lobo, C., Miguel, T. S., Conroy, J., et al. (2010) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2010.00627.x · Cited by 146 · cited 1×
“in BDNF level [10].”
Microtubule-associated polypeptides tau are altered in Alzheimer paired helical filaments
Grundke, I., VORBRODT, A. W., Iqbal, K., Tung, Y. C., Wang, G. P., & Wisniewski, H. M. (1988) · Molecular Brain Research · doi:10.1016/0169-328x(88)90017-4 · Cited by 138 · cited 1×
“Danvers, MA, USA); anti tau 92e (axonal marker, 1:10000; [24,25]; rabbit polyclonal anti- BDNF (N-20) (1:200 Santa Cruz Biotechnology, Santa Cruz, CA, USA ); rabbit polyclonal anti-”
BackgroundSelf-citationTruncated trkB Receptors on Nonneuronal Cells Inhibit BDNF-Induced Neurite Outgrowthin Vitro
Fryer, R. H., Kaplan, D. R., & Kromer, L. F. (1997) · Experimental Neurology · doi:10.1006/exnr.1997.6699 · Cited by 136 · cited 2×
“Cell Lines To study the activation of the TrkB receptor with BDNF and/ or with the peptides, we used NIH 3T3 cells (obtained from ATCC, Rockville, MD) stably transfected with the TrkB receptor (a kind gift from Dr. David Kaplan; Montréal Neurological Institute, Montréal, Québec, Canada [23].”
BackgroundYang, T., Knowles, J. K., Lu, Q., Zhang, H., Arancio, O., Moore, L. A., Chang, T., Wang, Q., Andreasson, K., Rajadas, J., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003604 · Cited by 130 · cited 1×
“Previous studies [52,53] reported the use of small Neurogenic/Neurotrophic BDNF Peptides”
ResultDesign of Potent Peptide Mimetics of Brain-derived Neurotrophic Factor
O'Leary, P. D., & Hughes, R. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303209200 · Cited by 129
Zhang, W., Liu, L.-Y., & Xu, T. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2007.12.037 · Cited by 126
Mandel, R. J. (2010) · PubMed · Cited by 121
Autonomic dysfunction in ALS: A preliminary study on the effects of intrathecal BDNF
Beck, M., Flachenecker, P., Magnus, T., Giess, R., Reiners, K., Toyka, K. V., & Naumann, M. (2005) · Amyotrophic Lateral Sclerosis · doi:10.1080/14660820510028412 · Cited by 117 · cited 2×
“Alternatively, direct administration of BDNF into the CNS to achieve beneficial neurotrophic effects is a promising approach [27–29], however, there are also some considerations with this strategy that need to be taken into account.”
BackgroundTatebayashi, Y., Iqbal, K., & Grundke-Iqbal, I. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-13-05245.1999 · Cited by 106 · cited 1×
“Danvers, MA, USA); anti tau 92e (axonal marker, 1:10000; [24,25]; rabbit polyclonal anti- BDNF (N-20) (1:200 Santa Cruz Biotechnology, Santa Cruz, CA, USA ); rabbit polyclonal anti-”
BackgroundSelf-citationAdenovirus in the brain: recent advances of gene therapy for neurodegenerative diseases
Barkats, M., Bilang‐Bleuel, A., Buc‐Caron, M., Castel-Barthe, M. N., Corti, O., Finiels, F., Horellou, P., Revah, F., Sabaté, O., & Mallet, J. J. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00028-8 · Cited by 99 · cited 1×
“One method to attain this can be gene delivery via adenoassociated viral vectors (AAVs) [30,31].”
MethodAnkeny, D. P., McTigue, D. M., Guan, Z., Yan, Q., Kinstler, O. B., Stokes, B. T., & Jakeman, L. B. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7699 · Cited by 96 · cited 2×
“Direct administration of BDNF into the CNS has been reported to cause weight loss, dysaesthesias (impairment of sensation), and in some cases, pain [27–29].”
BackgroundConditional reduction of adult neurogenesis impairs bidirectional hippocampal synaptic plasticity
Massa, F., Koehl, M., Wiesner, T., Grosjean, N., Revest, J.-M., Piazza, P.-V., Abrous, D. N., & Oliet, S. H. R. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016928108 · Cited by 94 · cited 1×
“This is in accordance with the proposed mechanisms of previously reported small molecules that mimetize partially the functions of BDNF [20,43–45].”
ResultLongo, F., Yang, T., Knowles, J., Xie, Y., Moore, L., & Massa, S. (2007) · Current Alzheimer Research · doi:10.2174/156720507783018316 · Cited by 90 · cited 2×
“diseases [19].”
BackgroundBlanchard, J., Wanka, L., Tung, Y.-C., Cárdenas-Aguayo, M. D. C., LaFerla, F. M., Iqbal, K., & Grundke-Iqbal, I. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0734-6 · Cited by 85
Self-citationDrug discovery and the human kinome: Recent trends
Eglen, R. M., & Reisine, T. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.007 · Cited by 85 · cited 1×
“Applications of small molecule mimetic drugs that target protein kinases involve not only neurological diseases, but also a variety of other disorders including obesity, metabolic syndrome, muscular degenerations, ulcerative lesions, diabetes, and cancer [42,60].”
BackgroundChohan, M. O., Li, B., Blanchard, J., Tung, Y. C., Heaney, A. T., Rabe, A., Iqbal, K., & Grundke, I. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.08.008 · Cited by 80 · cited 1×
“Also, previously, we described ciliary neurotrophic factor (CNTF) derived peptide mimetics which showed beneficial effects on neurogenesis, synaptogenesis, synaptic plasticity, and cognition in mouse and rat models of Alzheimer’s disease [54–59].”
BackgroundSelf-citationLi, N., & Liu, G.-T. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.3 · Cited by 79 · cited 1×
“late stages of the disease has been reported [3–7].”
BackgroundBolognin, S., Blanchard, J., Wang, X., Basurto-Islas, G., Tung, Y. C., Kohlbrenner, E., Grundke-Iqbal, I., & Iqbal, K. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0908-x · Cited by 78 · cited 1×
“Also, previously, we described ciliary neurotrophic factor (CNTF) derived peptide mimetics which showed beneficial effects on neurogenesis, synaptogenesis, synaptic plasticity, and cognition in mouse and rat models of Alzheimer’s disease [54–59].”
BackgroundSelf-citationHaase, G., Pettmann, B., Vigne, E., Castelnau, L., Schmalbruch, H., & Kahn, A. (1998) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(98)00207-x · Cited by 67 · cited 1×
“One method to attain this can be gene delivery via adenoassociated viral vectors (AAVs) [30,31].”
MethodHarper, M. M., Adamson-Small, L. A., Blits, B., Bunge, M. B., Grozdanić, S. D., & Sakaguchi, D. S. (2009) · Experimental Eye Research · doi:10.1016/j.exer.2009.05.013 · Cited by 67
Li, B., Wanka, L., Blanchard, J., Liu, F., Chohan, M. O., Iqbal, K., & Grundke-Iqbal, I. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.06.025 · Cited by 50 · cited 1×
“Also, previously, we described ciliary neurotrophic factor (CNTF) derived peptide mimetics which showed beneficial effects on neurogenesis, synaptogenesis, synaptic plasticity, and cognition in mouse and rat models of Alzheimer’s disease [54–59].”
BackgroundSelf-citationCárdenas‐Aguayo, M. D. C., Santa‐Olalla, J., Baizabal, J., Salgado, L. M., & Covarrubias, L. (2003) · Stem Cells and Development · doi:10.1089/15258160360732759 · Cited by 45
Blanchard, J., Chohan, M. O., Li, B., Liu, F., Iqbal, K., & Grundke, I. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1000069 · Cited by 45 · cited 1×
“Also, previously, we described ciliary neurotrophic factor (CNTF) derived peptide mimetics which showed beneficial effects on neurogenesis, synaptogenesis, synaptic plasticity, and cognition in mouse and rat models of Alzheimer’s disease [54–59].”
BackgroundSelf-citationSmall molecule cytokine mimetics
Whitty, A., & Borysenko, C. W. (1999) · Chemistry & Biology · doi:10.1016/s1074-5521(99)80034-9 · Cited by 39 · cited 1×
“This is in accordance with the proposed mechanisms of previously reported small molecules that mimetize partially the functions of BDNF [20,43–45].”
ResultFletcher, J. M., & Hughes, R. A. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.02.053 · Cited by 37 · cited 2×
“These peptides compare favorably to the BDNF derived cyclic peptides generated previously [43].”
BackgroundResultNeurotrophin-based strategies for neuroprotection
Longo, F. M., & Massa, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2004-6s606 · Cited by 34 · cited 1×
“Previous studies [52,53] reported the use of small Neurogenic/Neurotrophic BDNF Peptides”
ResultManfredsson, F. P., Bloom, D. C., & Mandel, R. J. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.03.001 · Cited by 29 · cited 1×
“However, this approach is now in evaluation, and it requires additional improvements to guarantee the safety of the patients [32,33].”
BackgroundBlanchard, J., Bolognin, S., Chohan, M. O., Rabe, A., Iqbal, K., & Grundke-Iqbal, I. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318236e9ad · Cited by 28 · cited 1×
“Also, previously, we described ciliary neurotrophic factor (CNTF) derived peptide mimetics which showed beneficial effects on neurogenesis, synaptogenesis, synaptic plasticity, and cognition in mouse and rat models of Alzheimer’s disease [54–59].”
BackgroundSelf-citationTrkB partial agonists: Potential treatment strategy for major depression
Tsai, S. (2006) · Medical Hypotheses · doi:10.1016/j.mehy.2006.06.019 · Cited by 22 · cited 1×
“While in the absence of a full agonist, partial agonists show functional agonist activity and bind to the receptor to produce a response [46–48].”
BackgroundTandem Repeat Peptide Strategy for the Design of Neurotrophic Factor Mimetics
Williams, G., Williams, G., Molina‐Holgado, F., Molina‐Holgado, F., Doherty, P., & Doherty, P. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708783885200 · Cited by 16 · cited 1×
“it’s poor blood brain barrier (BBB) and intraparenchymal penetrations [11].”
Background
Research works printed but not linked: 1
- C Behl, 2002, Antioxidant neuroprotection in Alzheimer’s disease as preventive and therapeutic approach, Free Radic Biol Med, 33, 182
Cited by
BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases
Lu, B., Nagappan, G., Guan, X., Nathan, P. J., & Wren, P. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3505 · Cited by 743
Gómez-Virgilio, L., Silva-Lucero, M.-D.-C., Flores-Morelos, D.-S., Gallardo-Nieto, J., Lopez-Toledo, G., Abarca-Fernandez, A.-M., Zacapala-Gómez, A.-E., Luna-Muñoz, J., Montiel-Sosa, F., Soto-Rojas, L. O., et al. (2022) · Cells · doi:10.3390/cells11152262 · Cited by 431
Neurobiology of BDNF in fear memory, sensitivity to stress, and stress-related disorders
Notaras, M., & van den Buuse, M. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0639-2 · Cited by 392
Engineering mesenchymal stem cells to improve their exosome efficacy and yield for cell‐free therapy
Phan, J., Kumar, P., Hao, D., Gao, K., Farmer, D., & Wang, A. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1522236 · Cited by 333
Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression
Levy, M. J. F., Boulle, F., Steinbusch, H. W., van den Hove, D. L. A., Kenis, G., & Lanfumey, L. (2018) · Psychopharmacology · doi:10.1007/s00213-018-4950-4 · Cited by 308
Metadata
- Authors
- Cardenas-Aguayo, M. D. C., Kazim, S. F., Grundke-Iqbal, I., & Iqbal, K.
- Affiliations
- State University of New York (US)
- Corresponding author
- Iqbal, Khalid
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-01-08
- Volume
- 8
- Issue
- 1
- Pages
- e53596
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3539976
- OpenAlex
- W2038374013
- Cited by
- 73
- References
- 62
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 5 · 2023: 3 · 2022: 6 · 2021: 4 · 2020: 6 · 2019: 6 · 2018: 9 · 2017: 3 · 2016: 7 · 2015: 2 · 2014: 7 · 2013: 6
- FWCI
- 3.60
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacological Receptor Mechanisms and Effects
- Keywords
- brain-derived neurotrophic factor, TrkB receptor, hippocampal neurons, neurotrophic peptides, TrkB phosphorylation, K252a, neuroprotection, neurodegenerative diseases
- MeSH terms
- Amino Acid Sequence, Animals, Cells, Cultured, Hippocampus, Molecular Sequence Data, Nerve Growth Factors, Neurons, Oligopeptides, Peptide Fragments, Biomarkers, Neuroprotective Agents, Brain-Derived Neurotrophic Factor, Receptor, trkB, Mice, Neurogenesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.